Get started

Health

Bellring Brands | BRBR | Long at $22.77Bellring Brands NYSE:BRBR , a consumer staples company focused on ready-to-drink protein shakes, powders, and bars. Its key brands are Premier Protein, Dymatize, and PowerBar. Technical Analysis Post-earnings, NYSE:BRBR fell through my "crash" simple moving average zone (green lines). This price area is often a location of algorithmic share accumulation. The final major stop is sometimes the my "major crash" zone (now between $15 and $20). However, the earnings results weren't terrible for $NYSE:BRBR. I think an overall market turn, recession announcement, or company debacle would be the only driving factors causing the price to hit near $15. Thus, in the near-term, there may be some temporary weakness, but the bounce today shows strength. Growth While slower than anticipated into 2026 (which many companies are reporting...), continued earnings and revenue growth into 2028 is anticipated: www.tradingview.com Health Cash king No long-term debt Very low bankruptcy risk (Altman's Z Score = 7+) Trading at a good 15x P/E Action NYSE:BRBR is still a high-growth company. I think the price movement recently has simply been a reset due to previous overvaluation. While the economy shows signs of weakness, the niche this Bellring Brands operates in is growing and shows strength. However, caution if there is a market downturn or recession announcement - $15 or lower isn't out of the question. Outside of that, though, continued growth may prop this company further beyond late 2025 / early 2026. Thus, at $22.77, NYSE:BRBR is in a personal buy zone. Targets into 2028 $30.00 (+31.8%) $39.00 (+71.3%)
NYSE:BRBRLong
by WorthlessViews
1
Can Integration Save CVS or Sink It?CVS Health confronts a dangerous convergence of risks that threatens its vertically integrated business model. The company's Pharmacy Benefit Manager (PBM) subsidiary, Caremark, faces intensifying regulatory scrutiny as lawmakers target the opaque rebate structures and spread pricing mechanisms that underpin PBM profitability. Simultaneously, the explosive growth of high-cost GLP-1 weight-loss drugs has created unprecedented formulary pressure. CVS's decision to exclude Eli Lilly's Zepbound in favor of Novo Nordisk's Wegovy, based purely on price, backfired spectacularly. Lilly publicly pulled its employees from CVS's PBM plan and shifted to competitor Rightway Healthcare, signaling deep market skepticism about CVS's ability to balance cost control with clinical outcomes. This defection validates concerns that major employers are increasingly willing to abandon the "Big Three" PBMs for transparent alternatives.   The company's acquisition strategy has proven economically disastrous, with CVS recording a staggering $5.7 billion goodwill impairment charge on Oak Street Health in Q3 2025, effectively admitting the primary care assets were dramatically overvalued. This massive write-down undermines the core thesis that vertical integration of insurance (Aetna), PBM (Caremark), and care delivery creates synergistic value. Meanwhile, operational margins erode from multiple directions: $833 million in litigation charges from past business practices, declining generic dispensing rates as expensive branded GLP-1 drugs displace generics, and the structural reality that robust patent protection on GLP-1 drugs extending into the 2040s eliminates the PBM's traditional leverage of threatening generic competition.   CVS faces additional systemic vulnerabilities across geopolitical, technological, and scientific domains. The company's reliance on Active Pharmaceutical Ingredients sourced from China and India exposes it to supply chain disruptions, tariffs, and mandatory but expensive domestic manufacturing mandates. Its vast integrated infrastructure creates an attractive single point of failure for cyberattacks, heightened by the $20 billion technology investment to further interconnect all segments. Most critically, pharmaceutical manufacturers hold unprecedented leverage due to the extended patent exclusivity of breakthrough GLP-1 therapies, with no meaningful generic relief for 15-20 years, forcing CVS into a perpetual choice between excluding superior drugs and losing clients, or accepting coverage that severely erodes margins.   Until CVS demonstrates sustainable PBM client retention among major employers, successful integration of its healthcare delivery assets without further impairments, and a viable strategy to navigate the regulatory assault on traditional PBM economics, the investment profile remains fundamentally challenged. The Lilly defection represents more than a single client loss; it exposes structural fragility in a business model increasingly misaligned with market demands for transparency, clinical appropriateness, and technological innovation.
NYSE:CVSShort
by UDIS_View
OSCR: back to support and now it’s decision timeAfter the recent impulse move, OSCR has pulled back to a key support zone around 13.65. That area aligns with the 0.79 Fib retracement, a horizontal level from spring, and a rising trendline that has already triggered reversals in the past. The structure is still intact, and buyers are testing the level again. If support holds and we get a bullish confirmation, the next target is 17.01, followed by a potential breakout toward the high at 22.81. Volume remains elevated, the overall structure is healthy, and the correction is controlled. A break below 13.00 would invalidate the setup - until then, it’s a clean, high-reward zone with tight risk. Fundamentally, Oscar Health has revised its 2025 guidance: revenue is expected in the $12–12.2B range, with operating losses projected between $200M and $300M. Despite softening topline growth, earnings per share are improving, and investor sentiment has been shifting. Technical strength is also reflected in the recent rise in RS Rating to 93, confirming that the stock is showing relative leadership even as the market cools. This is one of those setups where both technicals and narrative are aligning - now we just need confirmation from the chart.
NYSE:OSCRLong
by TotoshkaTrades
Molina Healthcare | MOH | Long at $181.69Healthcare providers and services are at a major discount right now: and may be discounted even more this year. I am personally buying and long-term holding the fear, knowing the baby boom generation is going to utilize our healthcare system at a rate unseen in modern times. While the price discounts are valid "right now" given the current political administration's cuts, long-term it is far from valid... The strategy I am using with healthcare stocks ( NYSE:MOH , NYSE:CNC , NYSE:UNH , NYSE:ELV , etc) is cost averaging: not buying one single large position in an effort to predict bottom but buying smaller positions over time to create a cost average "near" bottom. If you are a day trader or want a quick swing in healthcare, I don't think it's going to happen for a bit. But those not entering in the coming months / year will likely miss out on a very large healthcare boom - especially when AI truly enters the picture in this sector... Fundamentally, Molina Healthcare NYSE:MOH is a very strong company. Low debt-to-equity (.9x), P/E of 8.8x, quick ratio of 1.7x, $41 billion in revenue in 2024. Yes, there will be issues in the near-term due to Medicaid and other funding cuts. But long-term, this sector is primed to benefit from an aging population. So, while NYSE:MOH is in a personal buy zone at $181.69, I don't think this is necessarily bottom. I anticipate this stock to drop even further, eventually closing the daily price gap at $135.00. My next buys are in the $150's and $130's, thus cost averaging into a larger position. For true value investors, those prices and anything below is a steal. Today's negative healthcare sector noise is loud, but it does not represent the future. Targets into 2028: $226.00 (+24.3%) $290.00 (+59.6%)
NYSE:MOHLong
by WorthlessViews
OSCR 1W — When the Chart Speaks Before the FundamentalsThe Oscar Health chart is currently forming a textbook cup and handle — a long-term reversal structure that has completed its base and is now breaking out of the consolidation zone. The bullish structure is confirmed through price action, volume, and positioning relative to key moving averages. The price has broken through the upper boundary of the handle, shaped as a descending wedge. The breakout is accompanied by increased volume — a clear sign of capital rotation out of accumulation. All major moving averages (EMA, MA50, MA200, WMA) are trending upward, and the price is holding above them all, confirming the bullish momentum. According to Fibonacci extension levels, drawn from the historical low of $1.50 to the peak near $23.26, the first wave target stands at $36.71 (1.618 level), with an extended target at $45.02 (2.0 level). Structurally, the setup suggests a medium-term scenario pointing from current levels toward the $36–45 range, with the potential to repeat the kind of explosive move seen during the 2023 phase, when the price increased more than sixfold. On the fundamental side, Oscar Health is actively recovering: in 2024, revenue grew by more than 50%, net losses were cut nearly in half, and the client base continued to expand. The company is strengthening its share in the digital insurance market and gaining support from institutional investors, including Morgan Stanley and Capital Group. The latest quarterly report was positively received. The breakout is technically clean and fundamentally supported. The immediate pullback zones sit at $14.95 and $13.40. Below that, moving averages may act as control zones for reaction.
NYSE:OSCRLong
by TotoshkaTrades
VERTEX ($VRTX) SHINES IN Q4—PAIN & CF FUEL GROWTHVERTEX ( NASDAQ:VRTX ) SHINES IN Q4—PAIN & CF FUEL GROWTH (1/9) Good evening, Tradingview! Vertex ( NASDAQ:VRTX ) is buzzing—Q4 revenue up 16%, new drugs hit the scene 📈🔥. $ 2.91B and a bold 2025 forecast—let’s unpack this biotech beast! 🚀 (2/9) – REVENUE RUSH • Q4 Haul: $ 2.91B—16% jump from last year 💥 • Full ‘24: $ 11.02B, up 12%—Trikafta’s king 📊 • ‘25 Outlook: $11.75-$ 12B—6-9% growth NYSE:CF keeps humming—newbies add zest! (3/9) – BIG WINS • Journavx: Non-opioid painkiller greenlit Jan ‘25 🌍 • Alyftrek: CF drug for 6+—ships now 🚗 • Cash: $11.2B—loaded for action 🌟 NASDAQ:VRTX storms pain—CF stays golden! (4/9) – SECTOR CHECK • Valuation: 11x sales—above 9x avg 📈 • Vs. Peers: Gilead’s 4x, Regeneron’s 8x—premium? • Growth: 12% beats biotech’s 5-7% 🌍 NASDAQ:VRTX flexes—value or stretch? (5/9) – RISKS ON TAP • Payers: Journavx needs coverage—hiccups? ⚠️ • Trikafta: 93% of sales—big lean 🏛️ • Comp: Pain rivals, CF safe—for now 📉 Hot streak—can it dodge the bumps? (6/9) – SWOT: STRENGTHS • CF King: Trikafta, Alyftrek lock it in 🌟 • Pain Play: Journavx eyes $ 4B peak 🔍 • Cash: $11.2B—war chest ready 🚦 NASDAQ:VRTX ’s got muscle and moolah! (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES • Weaknesses: Trikafta reliance—eggs in one basket 💸 • Opportunities: Casgevy rolls, pain grows 🌍 Can NASDAQ:VRTX zap past the risks? (8/9) – NASDAQ:VRTX ’s Q4 surge—what’s your vibe? 1️⃣ Bullish—Pain pays off big. 2️⃣ Neutral—Solid, but risks linger. 3️⃣ Bearish—Growth hits a wall. Vote below! 🗳️👇 (9/9) – FINAL TAKEAWAY NASDAQ:VRTX ’s $2.91B Q4 and Journavx/Alyftrek wins spark buzz—$11.2B cash backs it 🌍🪙. Trikafta rules, risks hover—champ or chaser?
NASDAQ:VRTXLong
by DCAChampion
SOLID BIOSCIENCES—$SLDB CASHES UP FOR GENE THERAPY PUSHSOLID BIOSCIENCES— NASDAQ:SLDB CASHES UP FOR GENE THERAPY PUSH (1/9) Good afternoon, Tradingview! Solid Biosciences is stacking cash—no revenue yet, but a $200M raise has tongues wagging 📈🔥. NASDAQ:SLDB ’s betting big on gene therapy—here’s the scoop! 🚀 (2/9) – CASH, NOT SALES • Revenue: Zilch—clinical-stage vibes 💥 • Q3 ‘24 Loss: $0.61/share, missed $0.58 est. 📊 • Cash Boost: $200M offering just landed No sales, but NASDAQ:SLDB ’s war chest is growing! (3/9) – BIG MOVE • Feb 18 Raise: $200M via 35.7M shares, warrants 🌍 • Cash Pile: Was $171M, now nearing $350M 🚗 • Goal: Fuel SGT-003 trials into ‘27 🌟 NASDAQ:SLDB ’s loading up for the long haul! (4/9) – SECTOR CHECK • Market Cap: $500M post-raise 📈 • Vs. Peers: Sarepta’s 13B dwarfs it—revenue rules • Edge: Low EV ($150M), big therapy dreams Undervalued biotech bet or long shot? 🌍 (5/9) – RISKS ON DECK • Trials: SGT-003 flops could sink it ⚠️ • Sentiment: 30% drop from Jan peak—jitters 🏛️ • Burn: $20-25M/quarter—clock’s ticking 📉 High stakes, high risks—can it deliver? (6/9) – SWOT: STRENGTHS • Cash: $200M raise powers trials 🌟 • SGT-003: Early data dazzles, Fast Track nod 🔍 • DMD Focus: Huge need, blockbuster shot 🚦 NASDAQ:SLDB ’s got fuel and firepower! (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES • Weaknesses: No revenue, all-in on one play 💸 • Opportunities: $2-4B cap if trials pop 🌍 Can NASDAQ:SLDB turn cash into a cure? (8/9) – NASDAQ:SLDB ’s $200M haul—your take? 1️⃣ Bullish—Gene therapy gold ahead. 2️⃣ Neutral—Wait for trial proof. 3️⃣ Bearish—Risks outweigh the buzz. Vote below! 🗳️👇 (9/9) – FINAL TAKEAWAY NASDAQ:SLDB ’s revenue-free, but $200M keeps SGT-003 alive—stock’s buzzing 🌍🪙. Low EV vs. peers, yet trials and rivals loom. Cure or bust?
NASDAQ:SLDBLong
by DCAChampion
$UNH Bad News Longs.NYSE:UNH Recent news should (I believe will) put an end to the madness imaginary run from the corrupt world of health insurance. News circulating NYSE:UNH was a top denier of benefits and claims, only will get worse. A CEO involved in a hit sh**ting? They won't find the "guy" and I assume they will make an arrest but not the actual one who did it. Mmn, conspiracy, yes. But, similar pattern evolving on the chart as well, almost like it all makes sense. Might be a good time to short the health/insurance sector.. maybe.. BlueCross BlueShield just cut back on paying for patients anesthesia in NY, CT, and MO. They are against the people.. biggest ponzi-scheme ever. $555 target, break $500 I see $530. A lot of bearish flow poured in today as well. Months out puts. Not financial advice. wall street .. loser
NYSE:UNHShort
by fullbellytrading
ELI LILLY has at least +50% upside from here.Eli Lilly (LLY) has been trading within a 5-year Channel Up and last week closed below its 1W MA50 (blue trend-line) for the first time since the week of March 06 2023. Despite the bearish pressure of this Bearish Leg since July 15 2024, that last 1W MA50 closing was the previous Higher Low at the bottom of the Channel Up. The 1W RSI is on a similar level (just below 40.00) with all previous 4 major bottoms and the common characteristic of all was that the stock broke below the 1W MA50 but managed to keep clear and hold the 1W MA100 (green trend-line), practically the most important Support level of the market. If you want a confirmed buy entry, you might want to wait for yet another Bullish Cross on the 1W MACD (as it happened on all previous bottoms), otherwise this buy opportunity is good to go for at least +58% from the bottom (minimum rise among those 4 Bullish Legs). Our Target is $1135. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
5
JOHNSON & JOHNSON Excellent confirmed sell signalJohnson & Johnson (JNJ) gave us the most optimal buy entry on our last call (April 17, see chart below) and easily hit our 157.50 Target: Having been rejected early in September exactly at the top (Lower Highs trend-line) of the 2-year Channel Down and now establishing price action below its 1D MA50 (blue trend-line), this is a confirmed sell signal and the start of the Channel's 5th Bearish Leg. The RSI Lower Highs are common on all previous Channel tops. Our Target is 141.00, which is on the Internal Lower Lows trend-line (formed by the last 2 Lower Lows) and still above the 1.236 Fibonacci extension. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:JNJShort
by TradingShot
ELI LILLY Always a solid buy below its 1D MA50.Eli Lilly (LLY) broke on Friday below its 1D MA50 (blue trend-line) for the first time since August 09. As the stock trades within a long-term Channel Up since the March 01 2023 bottom, every time the price was below the 1D MA50, it didn't stay for long, thus providing the most effective buy entry. Even though it could dip some more as with July's decline (only such case though out of 6 corrections), as long as the 1D MA200 (orange trend-line) holds, we expect the Channel Up to be extended. The initial Higher Highs were closer to the 1.5 Fibonacci Channel extension, the last one however was exactly on the 1.0 Fib. As a result, we will take a more conservative Target on that trend-line, thus turning bullish now and aiming at $1100 by the end of the year. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
UNITED HEALTH forming a bottom.United Health (UNH) gave an excellent dip buy opportunity last time (March 29, see chart below), with the price even breaking above the long-term Resistance Zone eventually: The price has since entered a Channel Up pattern with the price now below its 1D MA50 (blue trend-line), having already topped and attempting to form a new Higher Low at the bottom of the pattern. Like the previous one in June, this bottoming process can take another 3 weeks, so we will time it accordingly and target 675.00 (+21.00% rise, similar to both previous Bullish Legs). ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:UNHLong
by TradingShot
Investors Await Q1 ReportKey arguments in support of the idea. ▪ UNH stock has come under pressure from a series of adverse events, though Q1 earnings may improve investor sentiment regarding further UNH business growth potential. ▪ A good moment for buying, both fundamentally and technically. Investment Thesis UnitedHealth Group (UNH) engages in the provision of health insurance, software, and related consulting services. UNH is the largest provider of healthcare plans in the US. In Early 2024, UNH’s Stock Came Under Pressure from Several Adversities at Once . First, it is a cyberattack on Change Healthcare services, that led to a temporary freeze on payments from medical organizations. At the time of finalizing this report, UnitedHealth informed that services were restored, and that it did not expect big implications for financial results. However, market participants fear a one-time negative impact on profitability in Q1 2024. Shortly after the cyberattack, it was reported that the US Department of Justice had initiated an antitrust investigation for examining the strength of relationship between UnitedHealth’s insurance and medical business divisions. The impact of the investigation is uncertain, and we do not believe it to influence the stock in the short term. Investors Were Disappointed by CMS’ Final Decision on Medicare Advantage (MA) Payment Rates. On April 2, MA plan rate rises for 2025 compared to 2024 became finally known. The payout rate remained at the proposed level of 3.7% y/y, disappointing investors looking for a bigger increase. This caused a negative market reaction: UNH, the largest player, ended the April 2 trading with a 9.3% drop. Some other major stocks reacted that day accordingly: HUM (-13.4%), CVS (-7.2%), ELV (-3.3%). The worsened MA business revenue expectations for 2025 are already reflected in prices. However, the Optum segment’s organic growth (OptumHealth, OptumInsight, and OptumRx) remains a strong point of the Company and may support its Q1 2024 results that will be released on April 16. Expectations for Q1 Report. We think that investors will be focused on the guidance for 2024. Management’s confirmation or improvement of the existing guidance could dispel investor worries. Besides, we expect a detailed commentary on the impact of the cyberattack and the MA rate decision on financial results. Now Is a Good Time to Buy. The P/E NTM ratio has decreased to 15.8, which is lower than the Company’s all-time average of 18.8. The RSI has dropped below 30 points, signaling a likely reversal. We consider UNH shares’ current weakness as a good opportunity to buy, assuming that (1) the impact of the approved MA 2025 rate is already reflected in prices, (2) the cyberattack will have a one-time insignificant implication for UNH, and (3) there is still a high demand in the MA market, and UNH remains the largest and growing provider of healthcare plans. The target price for UNH over a 2-month horizon is $495, which corresponds to P/E NTM of 18. We recommend Buying and setting a Stop Loss at $415.
NYSE:UNH
by FreedomHolding
Gaxos Acquires Rights to AI-enabled TechnologyGaxos.ai Inc., ( NASDAQ:GXAI ) a pioneering force in artificial intelligence (AI) applications, has announced a significant strategic move to bolster its presence in the health and wellness sector. The acquisition of rights to AI-enabled technology from the top biohacking app, Ultiself, marks a pivotal moment in Gaxos' journey towards revolutionizing the human-AI relationship. Unlocking Enhanced Customization and User Experience: The integration of Ultiself's proprietary technology into Gaxos Health's ( NASDAQ:GXAI ) product offering signifies a leap forward in personalized health solutions. By harnessing the power of AI, Gaxos aims to deliver unparalleled customization and efficiency to meet the evolving demands of modern consumers. This strategic move is poised to accelerate the development of Gaxos Health's AI-enabled application, paving the way for innovative diet, nutrition, and tracking capabilities. CEO's Vision for Innovation: Vadim Mats, CEO of Gaxos.AI, underscores the significance of securing the rights to this cutting-edge technology. With a focus on delivering value to customers and stakeholders, Mats envisions a future where Gaxos ( NASDAQ:GXAI ) redefines the human-AI relationship across diverse sectors, including health, wellness, and gaming. The commitment to leveraging AI solutions underscores Gaxos' dedication to addressing critical aspects of human well-being and entertainment. Collaborative Integration Process: The integration process between Gaxos ( NASDAQ:GXAI ) and Ultiself teams has commenced immediately, highlighting a collaborative approach to ensure a seamless transition. With both teams working in tandem, Gaxos endeavors to leverage Ultiself's technology to its fullest potential, driving innovation and enhancing user experiences. The synergy between Gaxos and Ultiself sets the stage for groundbreaking advancements in AI-enabled health solutions. Gaxos.ai's Vision for the Future: Gaxos.AI ( NASDAQ:GXAI ) isn't merely developing applications; it's pioneering a paradigm shift in the human-AI landscape. With a steadfast commitment to redefining health, longevity, and entertainment through AI solutions, Gaxos sets its sights on transformative innovation. The expansion into health and wellness represents a strategic pivot towards addressing fundamental human needs and shaping the future of AI-driven technologies. Technical Outlook Prior to the news, ( NASDAQ:GXAI ) stock surged by a whopping 50.38% trading above its 200-day Moving Average with a Relative Strength Index (RSI) of 63.54.
NASDAQ:GXAILong
by DEXWireNews
Hologic: Holding Above 200-week SMA Inside of a Cup with HandleHologic is currently Consolidating within the potential handle of a Bullish Cup with Handle pattern and is holding above the 200-week Simple Moving Average. If this pattern plays out successfully, the measured move target would take HOLX up to around $118. n addition to the technical pattern, HOLX seems to be improving its balance sheet on an annual basis, consistently increasing Assets while decreasing Liabilities and Debts. Overall, this stock seems like a stronger stock within the health sector.
NASDAQ:HOLXLong
by RizeSenpai